Resistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide Susceptibility in Mycobacterium tuberculosis

Abstract

Background and Objective

The relative contribution of nitric oxide (NO) to the killing of Mycobacterium tuberculosis in human tuberculosis (TB) is controversial, although this has been firmly established in rodents. Studies have demonstrated that clinical strains of M. tuberculosis differ in susceptibility to NO, but how this correlates to drug susceptibility and clinical outcome is not known.

Methods

In this study, 50 sputum smear- and culture-positive patients with pulmonary TB in Gondar, Ethiopia were included. Clinical parameters were recorded and drug susceptibility profile and spoligotyping patterns were investigated. NO susceptibility was studied by exposing the strains to the NO donor DETA/NO.

Results

Clinical isolates of M. tuberculosis showed a dose- and time-dependent response when exposed to NO. The most frequent spoligotypes found were CAS1-Delhi and T3_ETH in a total of nine known spoligotypes and four orphan patterns. There was a significant association between reduced susceptibility to NO (>10% survival after exposure to 1 mM DETA/NO) and resistance against first-line anti-TB drugs, in particular isoniazid (INH). Patients infected with strains of M. tuberculosis with reduced susceptibility to NO showed no difference in cure rate or other clinical parameters but a tendency towards lower rate of weight gain after two months of treatment, independent of antibiotic resistance.

Conclusion:

There is a correlation between resistance to first-line anti-TB drugs and reduced NO susceptibility in clinical strains of M. tuberculosis. Further studies including the mechanisms of reduced NO susceptibility are warranted and could identify targets for new therapeutic interventions.

About the Authors:

Jonna Idh

* E-mail: [email protected]

Affiliation: Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Mekidim Mekonnen

Affiliations Department of Microbiology, Immunology and Parasitology, Addis Ababa University, Debre Zeit, Ethiopia, Armauer Hansen Research Institute, Addis Ababa, Ethiopia

Ebba Abate

Affiliations Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden, Armauer Hansen Research Institute, Addis Ababa, Ethiopia, Department of Microbiology and Parasitology, Gondar University Hospital, Gondar, Ethiopia

Wassihun Wedajo

Affiliation: Armauer Hansen Research Institute, Addis Ababa, Ethiopia

Jim Werngren

Affiliation: Unit of Highly Pathogenic Microorganisms, Department of Preparedness, Swedish Institute for Communicable Disease Control, Solna, Sweden

Kristian Ängeby

Affiliation: Clinical Microbiology, MTC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

Maria Lerm

Affiliation: Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Daniel Elias

Affiliation: Department of Cancer and Inflammation, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Tommy Sundqvist

Affiliation: Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Abraham Aseffa

Affiliation: Armauer Hansen Research Institute, Addis Ababa, Ethiopia

Olle Stendahl

Affiliation: Division of Microbiology and Molecular Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Thomas Schön

Affiliation: Department of Infectious Diseases and Department of Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden

Introduction

An important part of the host defence against Mycobacterium tuberculosis is nitric oxide (NO) produced by activated macrophages from L-arginine, molecular oxygen, and NADPH through the activity of inducible NO synthase (iNOS) [1]. Several animal and macrophage experiments have shown that NO and related reactive nitrogen species (RNS) constitute a major host defence mechanism against intracellular pathogens including, M. tuberculosis in both the acute and the latent phases of infection [2], [3]. It has also been shown that RNS are actively produced in human tuberculosis (TB), although their relative importance is controversial [4]–[9]. We have previously found that patients with TB have lower levels of NO in exhaled air and lower levels of NO metabolites in urine, compared to healthy controls [10], and that nutritional supplements of L-arginine can mediate clinical improvement in HIV-negative TB patients [11], [12].

Bicyclic nitroimidazoles are drug candidates currently in phase II trials for the treatment of tuberculosis [13], [14]. They are prodrugs, and one of the active metabolites generates RNS, which has been suggested to mediate the major anaerobic effect of the drug [15], [16]. It has also been shown that NO can contribute to the antimycobacterial action of the prodrug isoniazid (INH) [17]. The exact mechanisms of INH action are not fully understood, but during activation by mycobacterial catalase-peroxidase (encoded by the katG gen), several INH-derived intermediates and free radicals have been suggested to be of importance [17], [18].

Since previous studies have shown that susceptibility of mycobacteria to RNS can be strain-dependent [19]–[24], we here investigated the impact of relative NO susceptibility of M. tuberculosis on the clinical course of TB and in relation to drug resistance.

Materials and Methods

Patients

Patients presented here have previously been described in a clinical trial on arginine-rich food supplementation (ClinicalTrials.gov identifier: NCT00857402) were smear-positive patients with pulmonary TB, given Directly Observed Treatment Short course (DOTS) at Gondar University Hospital, Ethiopia, were consecutively asked to participate in the study. The inclusion criteria were age 15 to 60 years, willingness to take part in the study and no known chronic disease except TB and HIV. Baseline data for age, sex, HIV serostatus, presence of BCG scar, body mass index (BMI), body temperature, cough and haemoptysis was registered. Chest X-ray findings were graded as minimal, moderate or far advanced TB [25], and after two months of treatment as normal, marked regression, regression, stable disease or progression. Laboratory parameters, erythrocyte sedimentation rate (ESR), baseline acid-fast bacilli (AFB) smear grade, and NO metabolites in urine (as described by Verdon et al [26]) were measured. In the first eleven included subjects, exhaled NO was registered using an chemiluminescence NO analyser (NIOX, Aerocrine AB, Sweden) as previously described [27].

Identification and Spoligotyping of M. tuberculosis

One sputum specimen from each patient was kept at −20°C (as presented before) [28]. The sputum was decontaminated (modified Petroff’s method) and processed according to standard protocols [29] with subsequent inoculation on Lowenstein Jensen (LJ) slant media. M. tuberculosis was identified by a PCR-based approach built on genomic deletion analysis [30], and was carried out as described [31]. Spoligotyping was performed using a standard protocol [32] with the oligonucleotides DRa and DRb to amplify the direct repeat (DR) regions.

Drug Susceptibility Testing

Drug susceptibility testing for streptomycin (SM, 2 mg/L), isoniazid (INH, 1 mg/L), ethambutol (EMB, 5 mg/L) and rifampin (RIF, 1 mg/L) was performed using the indirect proportion method on LJ media, as recommended by WHO [33], [34]. When bacterial growth on the antibiotic-free media reached 50–100 colonies, a growth more than 1% on antibiotic-containing media was classified as resistant.

Susceptibility Testing for Nitric Oxide

M. tuberculosis from LJ medium was cultured in Middlebrook 7H9 broth supplemented with oleic acid-albumin-dextrose-catalase (OADC) until log phase (determined by bacterial growth as colony forming units (CFU) at different incubation periods, data not shown). Following washing in sterile PBS/0.05% Tween 80, a final concentration of 107 CFU/mL of bacteria were exposed in duplicates to 1 mM diethylenetriamine/nitric oxide adduct (DETA/NO, Sigma-Aldrich) and PBS (control) separately in Middlebrook 7H9 medium without OADC for 24 hours at 37°C. M. tuberculosis H37Rv (H37Rv) and M. bovis BCG (BCG) were used as reference strains in dose-response studies. The antimicrobial effect of DETA/NO was determined by viable count (CFUs) in tenfold dilutions on Middlebrook 7H10 plates supplemented with glycerol and 10% OADC.

Ethical Considerations

This study was conducted according to the principles expressed in the Declaration of Helsinki and the study was approved by the ethics committees at the Research and Publication Office at Gondar College of Medicine and Health Sciences, Ethiopian Science and Technology Commission, and Karolinska Hospital, Sweden. All study subjects were included only after obtaining written informed consent. For children below 18 years informed and written consent was obtained from parents or guardians.

Statistical Analyses

Data are presented as median and rang or first and third quartiles (Q1–Q3) if not stated otherwise. Numerical data were analysed with Mann-Whitney U-test, discrete data with Pearson’s Chi-square test and Fisher’s exact test, and p-values of less than 0.05 were considered as statistically significant. Multiple logistic regression analysis with a stepwise correction was applied on variables with a p-value less than 0.1 in the univariate analysis.

Results

Baseline Characteristics

A total of 50 patients with confirmed culture- and smear-positive pulmonary TB were included in the study. The median age was 27 years (range 15–59), 50% (25/50) were female and 44% (22/50) were HIV-positive. Characteristics are presented in detail in table 1.

[Figure omitted. See PDF.]

Table 1. Characteristics for patients infected with strains of M. tuberculosis susceptible to NO or with reduced susceptibility to NO.

https://doi.org/10.1371/journal.pone.0039891.t001

Dose- and Time-dependent Response to NO

In order to determine doses and time points for the NO exposure, initial experiments with three randomly selected clinical isolates, one resistant to INH (coded RNI 027) and two fully susceptible to first-line anti-TB drugs (RNI 065 and RNI 066), were performed in duplicates. There was a dose- and time-dependent killing when exposed to DETA/NO (0.1–10 mM) (figure 1). After a 4-hour exposure to the selected dose of 1 mM DETA/NO, the mean survival rate of the strains for the clinical isolates was 68% (RNI 027), 62% (RNI 065), and 71% (RNI 066). In H37Rv and BCG, the survival rate was 45% and 57% respectively. The response was time-dependent and 24 hours post-exposure, the survival decreased to 23% (RNI 027), 13% (RNI 065) and 12% (RNI 066) for the clinical isolates and to 9% and 17% for H37Rv and BCG, respectively (figure 1b).

[Figure omitted. See PDF.]

Figure 1. Dose- and time-dependent killing of M. tuberculosis exposed to NO.

Survival of three clinical strains, H37Rv and BCG after exposure to 1 mM of the NO donor DETA/NO for 4 and 24 hours (A). Survival of the three clinical strains exposed to different doses of DETA/NO for 24 hours (B). Survival was determined through viable count (colony forming units, CFU) and each point represents a mean value of duplicates.

https://doi.org/10.1371/journal.pone.0039891.g001

Association between Reduced Susceptibility to NO and Resistance to First-line anti-TB Drugs

Drug susceptibility testing showed an overall resistance rate to first-line anti-TB drugs of 18% (9/50). The most frequent resistance was found against INH (10%, 5/50) followed by SM (6%, 3/50) and RIF (2%, 1/50). No strains resistant to EMB and no multidrug-resistant (MDR) TB strains were isolated in this study. The ratio of resistant strains did not differ between HIV-positive and HIV-negative individuals (14% (3/22) vs. 21% (6/28), p = 0.713).

The median survival in the 50 clinical isolates, 24 hours post exposure to 1 mM DETA/NO, was 10% and showed a variation between 0 to 60% when compared to a control exposed to PBS (p<0.001, figure 2). For further comparison of susceptibility to NO with drug resistance and clinical outcome, reduced susceptibility to DETA/NO was defined as >10% survival (1 log10) after exposure to 1 mM DETA/NO for 24 hours compared to the control exposed to PBS.

[Figure omitted. See PDF.]

Figure 2. Reduced NO susceptibility in spoligotype-based clusters of M. tuberculosis.

Survival of clinical isolates 24 hours after exposure to the NO donor DETA/NO. Presence of resistance to first-line anti-TB drugs is indicated with circles; isoniazid (INH), streptomycin (SM) and rifampin (RIF). Each point represents a mean value of duplicates and the dashed line is the median survival of all 50 isolates.

https://doi.org/10.1371/journal.pone.0039891.g002

Strikingly, no INH resistance was detected among NO-susceptible strains and the median survival of INH-resistant isolates exposed to DETA/NO was 53% (Q1–Q3, 32–57%, n = 5) compared to 10% (Q1–Q3, 0–25%, n = 45, p = 0.006) in INH-susceptible isolates.

Clinical Response in Relation to NO Susceptibility of M. tuberculosis

Infection with strains of M. tuberculosis with reduced susceptibility to NO did not correlate to the final clinical outcome according to WHO (cured, died, treatment failure, defaulter or transferred out; table 1), but there was a tendency to a lower rate of weight gain after 8 weeks of treatment (83% (20/24) vs. 100% (25/25), p = 0.05). Three out of the four study subjects who did not increase in weight during the 8 first weeks of treatment were HIV-positive, but there was no statistical difference in weight gain overall between HIV-positive and HIV-negative TB patients (86% (18/21) vs. 96% (27/28), p = 0.301). Nor did patients infected with drug-resistant strains differ in their rate of weight gain compared to patients with drug-susceptible strains (8/9, 89% vs. 37/40, 93%, p = 0.569).

Multiple Logistic Regression Analysis

The multiple logistic regression analysis showed that reduced NO susceptibility was associated to drug resistance also when age, sex, HIV status and supplementation of arginine-rich food were included in in the analysis (OR 19.00; 95% CI (1.67–215.52), p = 0.019, n = 50, table 2).

[Figure omitted. See PDF.]

Table 2. Multiple logistic regression analysis comparing strains of M. tuberculosis susceptible to NO with strains of reduced susceptibility to NO.

https://doi.org/10.1371/journal.pone.0039891.t002

Spoligotype Patterns

Of the 50 clinical strains 47 (94%) were successfully typed by conventional spoligotyping technique [32]. The isolates were identified as five orphan spoligotypes and nine spoligotypes present in the M. tuberculosis molecular markers database (SITVIT) and compared to the fourth international spoligotyping database (SpolDB4) for classification [35]–[37]. The most common spoligotypes were CAS1-Delhi (28%, 13/47) and T3_ETH (23%, 11/47). Although the spoligotype-based clusters differed in susceptibility to NO, our sample size was not sufficient to investigate any significant differences between the clusters (figure 2).

Discussion

The main finding of this study is that reduced susceptibility to NO in clinical strains of M. tuberculosis was associated with resistance to first-line drugs against TB. As previously reported, certain strains of M. tuberculosis can to some extent resist RNS generated in vitro as acidified nitrite (M. intracellulare 31F093T, KUMS 9007 [19], M. tuberculosis CDC1551, CB3.3 [23], M. bovis, M. tuberculosis 79499 [21], a C strain cluster defined by IS6110-based strain-typing [20], and the genotypes G1, G2, S2, U [24]). Since the acid has a bactericidal effect in itself and actually potentiates the effect of NO [38], it has been acknowledged that the new generation NO donors (DETA/NO) can better mimic a prolonged release with low levels of NO similar to the production in vivo [39]. In dose-response experiments for three clinical strains, we found that there was a dose-dependent killing by one log10 at 1 mM DETA/NO and by 2 log10 for 10 mM DETA/NO. The level of inhibition by NO at 24 hours was between 0.5 to 2 log10 for 1 mM DETA/NO, which could be compared to the early effect of bactericidal drugs such as INH [40]. To discriminate difference in susceptibility to NO between clinical strains, we used a cut-off for reduced NO susceptibility at 10% survival after 24 hours compared to control, which is similar to the wild type distribution used for defining critical concentrations for M. tuberculosis [33]. Lower doses of DETA/NO have been used to induce expression of latency-associated genes such as dosR [41], [42]. The effect of NO is likely to be increased if investigated at later time points as for anti-TB drugs, since killing of M. tuberculosis takes more time relative to other bacteria with higher replication rates such as E. coli. The analysis was blinded to antibiotic resistance data, and a high level of antibiotic resistance was observed in the isolates with reduced NO susceptibility. Strikingly, no INH resistance was detected among NO-susceptible strains but on the other hand reduced NO susceptibility was not exclusively found among INH-resistant strains. INH is a prodrug that needs activation by the katG-encoded mycobacterial catalase-peroxidase, where several INH-derived intermediates including free radicals have been suggested to contribute to the overall antimycobacterial action of INH [17], [18]. We did not verify the genetic location of the INH resistance, although the katG-mutation is the predominant cause of INH resistance in strains of M. tuberculosis from Ethiopia [43]. It has previously been shown that the loss of katG could render the bacteria susceptible to reactive oxygen species (ROS) and RNS, and a compensatory up-regulation of the alkyl hydroperoxidase (ahpC) gene could be the explanation for the increased resistance to NO as a compensatory survival strategy of INH-resistant bacteria [44]–[46]. Other candidates for antioxidant systems up-regulated by M. tuberculosis during oxidative stress are thioredoxin-dependent peroxidases (TPx), resulting in tolerance to peroxides produced by the immune system [42]. Most likely, it is a combination of the expression of genes upon exposure to reactive species, the resistance of the M. tuberculosis cell wall itself, and up-regulation of genes to repair damaged proteins and DNA, that result in reduced susceptibility against ROS and RNS in M. tuberculosis [42]. The most frequent spoligotypes were CAS1Delhi and T3_ETH and a more accurate identification of genetic relationship among the isolates is likely to better have identified differences among the strains in respect to susceptibility to NO.

Although the small sample size is a limitation, no correlation was found between susceptibility of M. tuberculosis to NO and treatment outcome, but there was a tendency towards lower rate of weight gain after 8 weeks of treatment, in subjects infected with M. tuberculosis with reduced susceptibility to NO. To draw a more definitive conclusion on whether this result was confounded by the presence of antimycobacterial drug resistance, a larger sample size is needed.

In a situation of increasing MDR and extensively drug-resistant (XDR) TB, new drug targets are needed [47]. NO is produced in activated macrophages during TB [1], [8], [9] and based on the correlation between reduced susceptibility to NO and resistance to first-line anti-TB drugs, the relative importance of oxidative defence mechanisms in M. tuberculosis needs to be further investigated.

Acknowledgments

The authors wish to thank Nurse Meseret Senbeto, Mr Tezera Jemere, Ms Saba Ekubay, and Mr Belay Anagaw for invaluable support in monitoring patients and handling patient samples. We also wish to thank the study participants without whom the study would not have been possible.

Author Contributions

Conceived and designed the experiments: JI MM JW KÃ, DE T. Sundqvist AA OS T. Schön. Performed the experiments: JI MM WW. Analyzed the data: JI MM ML T. Sundqvist OS T. Schön. Contributed reagents/materials/analysis tools: AA OS T. Schön. Wrote the paper: JI MM EA WW JW KÄ ML DE T. Sundqvist AA OS T. Schön.

Citation: Idh J, Mekonnen M, Abate E, Wedajo W, Werngren J, Ängeby K, et al. (2012) Resistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide Susceptibility in Mycobacterium tuberculosis. PLoS ONE7(6): e39891. https://doi.org/10.1371/journal.pone.0039891

References

1. Nathan C, Shiloh MU (2000) Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A 97: 8841–8848.C. NathanMU Shiloh2000Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens.Proc Natl Acad Sci U S A9788418848

2. Chan ED, Chan J, Schluger NW (2001) What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol 25: 606–612.ED ChanJ. ChanNW Schluger2001What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge.Am J Respir Cell Mol Biol25606612

3. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, et al. (2001) The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 69: 7711–7717.CA ScangaVP MohanK. TanakaD. AllandJL Flynn2001The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice.Infect Immun6977117717

4. Liu PT, Modlin RL (2008) Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20: 371–376.PT LiuRL Modlin2008Human macrophage host defense against Mycobacterium tuberculosis.Curr Opin Immunol20371376

5. Nicholson S, Bonecini-Almeida Mda G, Lapa e SilvaJR, Nathan C, Xie QW, et al. (1996) Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 183: 2293–2302.S. NicholsonG. Bonecini-Almeida MdaSilvaJR Lapa eC. NathanQW Xie1996Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis.J Exp Med18322932302

6. Rich EA, Torres M, Sada E, Finegan CK, Hamilton BD, et al. (1997) Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber Lung Dis 78: 247–255.EA RichM. TorresE. SadaCK FineganBD Hamilton1997Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB.Tuber Lung Dis78247255

7. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, et al. (1998) 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 66: 5314–5321.KA RockettR. BrookesI. UdalovaV. VidalAV Hill19981,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line.Infect Immun6653145321

8. Schon T, Elmberger G, Negesse Y, Pando RH, Sundqvist T, et al. (2004) Local production of nitric oxide in patients with tuberculosis. Int J Tuberc Lung Dis 8: 1134–1137.T. SchonG. ElmbergerY. NegesseRH PandoT. Sundqvist2004Local production of nitric oxide in patients with tuberculosis.Int J Tuberc Lung Dis811341137

9. Choi HS, Rai PR, Chu HW, Cool C, Chan ED (2002) Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med 166: 178–186.HS ChoiPR RaiHW ChuC. CoolED Chan2002Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis.Am J Respir Crit Care Med166178186

10. Idh J, Westman A, Elias D, Moges F, Getachew A, et al. (2008) Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection. BMC Infect Dis 8: 146.J. IdhA. WestmanD. EliasF. MogesA. Getachew2008Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection.BMC Infect Dis8146

11. Macallan DC (1999) Malnutrition in tuberculosis. Diagn Microbiol Infect Dis 34: 153–157.DC Macallan1999Malnutrition in tuberculosis.Diagn Microbiol Infect Dis34153157

12. Schon T, Elias D, Moges F, Melese E, Tessema T, et al. (2003) Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur Respir J 21: 483–488.T. SchonD. EliasF. MogesE. MeleseT. Tessema2003Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis.Eur Respir J21483488

13. Nathan C (2008) Microbiology. An antibiotic mimics immunity. Science 322: 1337–1338.C. Nathan2008Microbiology. An antibiotic mimics immunity.Science32213371338

14. Gurumurthy M, Mukherjee T, Dowd CS, Singh R, Niyomrattanakit P, et al. (2012) Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J 279: 113–125.M. GurumurthyT. MukherjeeCS DowdR. SinghP. Niyomrattanakit2012Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.FEBS J279113125

15. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392–1395.R. SinghU. ManjunathaHI BoshoffYH HaP. Niyomrattanakit2008PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.Science32213921395

16. Manjunatha U, Boshoff HI, Barry CE (2009) The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2: 215–218.U. ManjunathaHI BoshoffCE Barry2009The mechanism of action of PA-824: Novel insights from transcriptional profiling.Commun Integr Biol2215218

17. Timmins GS, Master S, Rusnak F, Deretic V (2004) Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3006–3009.GS TimminsS. MasterF. RusnakV. Deretic2004Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis.Antimicrob Agents Chemother4830063009

18. Timmins GS, Deretic V (2006) Mechanisms of action of isoniazid. Mol Microbiol 62: 1220–1227.GS TimminsV. Deretic2006Mechanisms of action of isoniazid.Mol Microbiol6212201227

19. Doi T, Ando M, Akaike T, Suga M, Sato K, et al. (1993) Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun 61: 1980–1989.T. DoiM. AndoT. AkaikeM. SugaK. Sato1993Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis.Infect Immun6119801989

20. Friedman CR, Quinn GC, Kreiswirth BN, Perlman DC, Salomon N, et al. (1997) Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis 176: 478–484.CR FriedmanGC QuinnBN KreiswirthDC PerlmanN. Salomon1997Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis.J Infect Dis176478484

21. O’Brien L, Carmichael J, Lowrie DB, Andrew PW (1994) Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun 62: 5187–5190.L. O’BrienJ. CarmichaelDB LowriePW Andrew1994Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro.Infect Immun6251875190

22. Rhoades ER, Orme IM (1997) Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun 65: 1189–1195.ER RhoadesIM Orme1997Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates.Infect Immun6511891195

23. Firmani MA, Riley LW (2002) Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro. Infect Immun 70: 3965–3968.MA FirmaniLW Riley2002Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro.Infect Immun7039653968

24. Inumaru VT, Nogueira PA, Butuem IV, Riley LW, Ferrazoli L (2009) Reactive nitrogen intermediate susceptibility of Mycobacterium tuberculosis genotypes in an urban setting. Int J Tuberc Lung Dis 13: 665–668.VT InumaruPA NogueiraIV ButuemLW RileyL. Ferrazoli2009Reactive nitrogen intermediate susceptibility of Mycobacterium tuberculosis genotypes in an urban setting.Int J Tuberc Lung Dis13665668

25. American ST (1961) National tuberculosis association of the USA diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association. ST American1961National tuberculosis association of the USA diagnostic standards and classification of tuberculosis.New York: National Tuberculosis Association

26. Verdon CP, Burton BA, Prior RL (1995) Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem 224: 502–508.CP VerdonBA BurtonRL Prior1995Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite.Anal Biochem224502508

27. Schon T, Idh J, Westman A, Elias D, Abate E, et al. (2011) Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis - A randomised trial. Tuberculosis (Edinb) 91: 370–377.T. SchonJ. IdhA. WestmanD. EliasE. Abate2011Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis - A randomised trial.Tuberculosis (Edinb)91370377

28. Mekonen M, Abate E, Aseffa A, Anagaw B, Elias D, et al. (2010) Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia. Ethiop Med J 48: 203–210.M. MekonenE. AbateA. AseffaB. AnagawD. Elias2010Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia.Ethiop Med J48203210

29. (HPA). HPA (2003) Standard Operating Procedure: investigation of specimens for mycobacterium species. (HPA). HPA2003Standard Operating Procedure: investigation of specimens for mycobacterium species.

30. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, et al. (2002) A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99: 3684–3689.R. BroschSV GordonM. MarmiesseP. BrodinC. Buchrieser2002A new evolutionary scenario for the Mycobacterium tuberculosis complex.Proc Natl Acad Sci U S A9936843689

31. Parsons LM, Brosch R, Cole ST, Somoskovi A, Loder A, et al. (2002) Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J Clin Microbiol 40: 2339–2345.LM ParsonsR. BroschST ColeA. SomoskoviA. Loder2002Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis.J Clin Microbiol4023392345

32. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, et al. (1997) Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907–914.J. KamerbeekL. SchoulsA. KolkM. van AgterveldD. van Soolingen1997Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.J Clin Microbiol35907914

33. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 21–43.G. CanettiW. FoxA. KhomenkoHT MahlerNK Menon1969Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.Bull World Health Organ412143

34. NCCLS NCfCLS (2000) Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes;tentative standard – second edition. NCCLS document M24-T2. NCfCLS NCCLS2000Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes;tentative standard – second edition.NCCLS document M24-T2

35. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, et al. (2006) Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6: 23.K. BrudeyJR DriscollL. RigoutsWM ProdingerA. Gori2006Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.BMC Microbiol623

36. Institut GldP (2011) SITVITWEB. Institut GldP2011SITVITWEB.Available: http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/.Accessed 2011 Oct. Accessed 2011 Oct.

37. Demay C, Liens B, Burguiere T, Hill V, Couvin D, et al. (2012) SITVITWEB - A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol 12: 755–766.C. DemayB. LiensT. BurguiereV. HillD. Couvin2012SITVITWEB - A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology.Infect Genet Evol12755766

38. Jackett PS, Aber VR, Lowrie DB (1978) Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol 104: 37–45.PS JackettVR AberDB Lowrie1978Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis.J Gen Microbiol1043745

39. Keefer LK, Nims RW, Davies KM, Wink DA (1996) “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 268: 281–293.LK KeeferRW NimsKM DaviesDA Wink1996“NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms.Methods Enzymol268281293

40. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, et al. (2007) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51: 2329–2336.T. GumboA. LouieW. LiuD. BrownPG Ambrose2007Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Antimicrob Agents Chemother5123292336

41. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al. (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198: 705–713.MI VoskuilD. SchnappingerKC ViscontiMI HarrellGM Dolganov2003Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.J Exp Med198705713

42. Voskuil MI, Bartek IL, Visconti K, Schoolnik GK (2011) The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol 2: 105.MI VoskuilIL BartekK. ViscontiSchoolnik GK2011The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species.Front Microbiol2105

43. Abate G, Hoffner SE, Thomsen VO, Miorner H (2001) Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 20: 329–333.G. AbateSE HoffnerVO ThomsenH. Miorner2001Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG.Eur J Clin Microbiol Infect Dis20329333

44. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, et al. (1996) Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641–1643.DR ShermanK. MdluliMJ HickeyTM ArainSL Morris1996Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.Science27216411643

45. Chen L, Xie QW, Nathan C (1998) Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. Mol Cell 1: 795–805.L. ChenQW XieC. Nathan1998Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates.Mol Cell1795805

46. Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK (1999) AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors 10: 211–217.Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK1999AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis.Biofactors10211217

47. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830–1843.NR GandhiP. NunnK. DhedaHS SchaafM. Zignol2010Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.Lancet37518301843